No press releases found.
Market Chameleon (Mon, 20-Oct 7:08 AM ET)
$11 Million Private Placement Reflects Confidence in TAOX's DeAI Strategy
Market Chameleon (Tue, 14-Oct 5:42 AM ET)
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
Tao Synergies trades on the NASDAQ stock market under the symbol TAOX.
As of April 30, 2026, TAOX stock price climbed to $5.13 with 161,665 million shares trading.
TAOX has a beta of 1.39, meaning it tends to be more sensitive to market movements. TAOX has a correlation of 0.02 to the broad based SPY ETF.
TAOX has a market cap of $36.57 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that TAOX belongs to (by Net Assets): VXF, DFAS, DFMC.
TAOX support price is $4.43 and resistance is $5.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TAOX shares will trade within this expected range on the day.
